Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    10384139 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
2 Active, not recruiting Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Conditions: Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions: Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
3 Completed QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
Condition: Multiple Myeloma
Intervention: Procedure: Maintenance with lower doses of lenalidomide and dexamethasone

Indicates status has not been verified in more than two years